about
Pharmacologic resistance in colorectal cancer: a reviewBiomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerHigh expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancerCorrelating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell linesEpidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenograftsCA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Epidermal growth factor inhibition in solid tumours.Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.Pharmacogenetics of colorectal cancer.PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Protein therapeutics: new applications for pharmacogenetics.Cetuximab in the treatment of metastatic colorectal cancer.Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.Biological therapy update in colorectal cancer.Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesCurrent role of antibody therapy in patients with metastatic colorectal cancer.Her signaling in pancreatic cancer.Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice.Combining chemotherapy and targeted therapies in metastatic colorectal cancer.EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.DNA/RNA markers for colorectal cancer risk in preserved stool specimens: a pilot study.Predictive and prognostic markers in colorectal cancer.PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancerCombined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerTargeted therapy of cancer: new roles for pathologists in colorectal cancer.Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
P2860
Q26769850-C30ACB3B-4E12-4A2C-86A1-D31BB000058BQ26774605-2777D536-67A1-4107-9C5F-7DF78D6E309CQ33348043-CB14BBFD-6F62-42CD-8304-A150377610DAQ33359798-972F0976-8B41-42FA-A745-4172F1C74FDCQ33429478-8DC5ABF4-6D0C-430C-BC23-2729BE3C6438Q33441143-C22DE396-AF14-493C-B2B5-C0550E1A60E1Q34068174-3D2E31A1-4AA7-4BA6-90D2-A0836CBF32A1Q34239801-EDBC92BD-B621-44C6-BF8C-E14B2C5A5E21Q34406526-85C0850A-56F6-41E6-BE9D-CD7649AF62C6Q34778496-84616FA8-1C15-4AC7-981D-636469F5B8D5Q35034638-FBB8356E-8D3F-4738-89AF-62B2C3652BD2Q35346509-02A28565-CAE5-4934-A2CB-D6463BA1DEFBQ35584153-942DA7D5-4286-40E2-A7DE-01F18E7062C0Q35773077-1FAEA037-B797-453E-A741-45AB9EFBBCEBQ35894601-9DAD151D-3667-45C0-89A6-9A67DE213907Q36012730-D523EB5E-719D-49A4-B384-E0F701F89A3AQ36239648-1B8B2752-FBE9-4918-B566-FEA0B80062E0Q36249234-3FF302A3-6225-454C-9971-E938CB897358Q36306554-D8B5FF1E-D948-4F38-BF19-4AE3111BBB73Q36326214-B5A38694-5424-493D-A8B7-4331909EB077Q36335893-E7FE19DB-7AD7-4F5A-BCA0-B5B714166342Q36482542-F54AC054-03ED-4147-B3E7-6FBBE04E941EQ36501235-C1A79DB3-F160-42C7-B2E5-E42D1CA5F765Q36717359-6BC472DB-A86B-4860-9A48-7DF64E45AA5CQ36717363-F1594E28-F159-499F-94C3-19CE0F9D0E48Q36764932-A01DAC82-E8A5-44D8-B249-1B7F4DEC8667Q36788485-628DB24F-B231-4B6E-AC92-17EAC7F6FFBAQ36793661-E86FCD77-19A1-4CFE-B7EB-961101835932Q36812355-DF8BC054-35BA-4530-BF08-672605030561Q36832121-CD0DE56B-546C-4283-8F52-72348C0F4B78Q36842715-C6166E7E-8D58-419D-BEC5-DC31E6B52265Q36977583-3FCFCDC4-70CF-4E4E-B8C6-40D00FCAC9A1Q36996324-15043765-DCD6-4870-AF35-8A420DB2F114Q37043503-95CE28C1-273D-4C3C-A4FF-0F7FB0DC2F6CQ37064970-35CB240E-3192-4D11-BB2C-54FDE3CCD9B0Q37073444-819ED6AF-56DD-4C9D-9A9D-DEB056251023Q37137091-C9501B5E-A996-45E3-A2DC-95FAE07C962DQ37146300-EEBECE14-7B33-4BB7-96F6-B7EF35DF5345Q37147762-69FA312B-EDFE-40D9-A6D5-8CA2A1A2013EQ37160656-B5943796-6DE9-4A6E-8020-98484E93C744
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Molecular determinants of cetuximab efficacy.
@ast
Molecular determinants of cetuximab efficacy.
@en
type
label
Molecular determinants of cetuximab efficacy.
@ast
Molecular determinants of cetuximab efficacy.
@en
prefLabel
Molecular determinants of cetuximab efficacy.
@ast
Molecular determinants of cetuximab efficacy.
@en
P2093
P356
P1476
Molecular determinants of cetuximab efficacy.
@en
P2093
Andy E Sherrod
Daniel Vallböhmer
Dong Yun Yang
Kathleen D Danenberg
Katrin E Rhodes
Michael Gordon
Oliver A Press
Susan Groshen
Syma Iqbal
P304
P356
10.1200/JCO.2005.09.100
P407
P577
2005-05-01T00:00:00Z